Verteporfin
别名: CL 318952
中文名称:维替泊芬
目录号:S1786 Purity: 99.31%
此产品请避光密封保存。
Verteporfin是一种能够抑制YAP-TEAD相互作用的小分子化合物,抑制YAP诱导的肝脏过度生长。同时,它还是一种有效的衍生自卟啉的第二代光敏剂。Verteporfin 是一种自噬抑制剂。Verteporfin 可抑制细胞增殖并诱导凋亡。
CAS: 129497-78-5
客户使用Selleck的Verteporfin发表文献141篇
- Nature, 2021 10.1038/s41586-021-04267-8
- Cell Res, 2021 10.1038/s41422-021-00477-x
- Cancer Cell, 2019 36(3):302-318
- Cancer Cell, 2018 33(2):292-308
- Nature, 2015 519(7541):57-62
- Biochem Pharmacol, 2025 231:116641
- Acta Pharm Sin B, 2024 14(3):1222-1240
- Bone Res, 2024 12(1):12
- Cancer Lett, 2024 587:216692
- J Pathol, 2024 10.1002/path.6282
- Mol Oncol, 2024 10.1002/1878-0261.13749
- Stem Cell Reports, 2024 19(4):501-514
- iScience, 2024 27(3):109125
- Cancer Sci, 2024 10.1111/cas.16292
- Int Immunopharmacol, 2024 141:112966
- Sci Rep, 2024 14(1):4060
- Invest Ophthalmol Vis Sci, 2024 65(13):32
- Ann Med, 2024 56(1):2313680
- Cell Death Dis, 2023 10.1038/s41419-023-06076-5
- Cell Death Dis, 2023 10.1038/s41419-023-06053-y
- Commun Biol, 2023 6(1):431
- Biomedicines, 2023 11(10)2692
- Sci Rep, 2023 13(1):8492
- Regen Ther, 2023 24:256-266
- Int J Med Sci, 2023 20(1):125-135
- FEBS Open Bio, 2023 10.1002/2211-5463.13618
- Sci Adv, 2023 9(22):eadg0478
- Acta Pharmaceutica Sinica B, 2023 10.1016/j.apsb.2023.12.007
- Nat Commun, 2022 13(1):3117
- Nat Commun, 2022 13(1):50
- Redox Biol, 2022 54:102384
- Research (Wash D C), 2022 2022:9825916
- Acta Biomater, 2022 152:300-312
- Int J Biol Sci, 2022 18(11):4497-4512
- Int J Biol Sci, 2022 18(10):3961-3980
- Int J Biol Sci, 2022 18(5):2202-2219
- Cell Prolif, 2022 e13315
- Oxid Med Cell Longev, 2022 2022:9974639
- J Pathol, 2022 10.1002/path.5910
- Cell Death Discov, 2022 8(1):499
- iScience, 2022 25(7):104618
- Cancer Sci, 2022 113(12):4104-4119
- Front Endocrinol (Lausanne), 2022 13:813165
- J Biol Chem, 2022 S0021-9258(22)00232-0
- Am J Physiol Renal Physiol, 2022 322(5):F512-F526
- Exp Cell Res, 2022 411(1):113000
- Biomed Res Int, 2022 2022:3215461
- Exp Dermatol, 2022 31(10):1477-1499
- Hum Mol Genet, 2022 ddab374
- Hepatobiliary Pancreat Dis Int, 2022 S1499-3872(22)00136-9
- Pediatr Blood Cancer, 2022 e29705
- Connect Tissue Res, 2022 1-16
- In Vitro Cell Dev Biol Anim, 2022 58(8):658-668
- Nat Commun, 2021 12(1):3055
- Hepatology, 2021 74(5):2605-2621
- J Exp Clin Cancer Res, 2021 40(1):23
- Cancer Res, 2021 81(22):5652-5665
- Proc Natl Acad Sci U S A, 2021 118(29)e2024853118
- Cell Death Dis, 2021 12(1):121
- Cell Chem Biol, 2021 S2451-9456(21)00442-6
- Biomed Pharmacother, 2021 138:111506
- Cancer Gene Ther, 2021 10.1038/s41417-021-00335-3
- Oncogenesis, 2021 10(1):2
- Front Cell Dev Biol, 2021 9:660159
- Cancers (Basel), 2021 13(21)5474
- Sci Rep, 2021 11(1):3259
- Sci Rep, 2021 11(1):3857
- Lipids Health Dis, 2021 20(1):74
- Immunol Lett, 2021 242:8-16
- Front Physiol, 2021 12:732084
- Pharm Biol, 2021 59(1):619-628
- Mol Med Rep, 2021 24(5)789
- Mol Med Rep, 2021 24(1)487
- Med Oncol, 2021 38(4):41
- J Asthma Allergy, 2021 14:839-850
- Oncol Lett, 2021 22(2):597
- Nat Commun, 2020 11(1):5679
- Nat Commun, 2020 11(1):4788
- Nat Commun, 2020 11(1):4766
- Cell Death Differ, 2020 10.1038/s41418-020-00677-9
- J Exp Clin Cancer Res, 2020 3;39(1):102
- J Neuroinflammation, 2020 17(1):322
- Cell Rep, 2020 30(1):37-45
- NPJ Precis Oncol, 2020 25;4:7
- Elife, 2020 30;9:e55771
- Biomater Sci, 2020 8(17):4779-4791
- Cancer Sci, 2020 10.1111/cas.14546
- Front Cell Dev Biol, 2020 8:853
- Burns Trauma, 2020 8:tkaa029
- J Zhejiang Univ Sci B, 2020 21(9):703-715
- Transl Oncol, 2020 13(1):70-78
- Front Oncol, 2020 10:1781
- Sci Rep, 2020 10(1):21018
- J Dermatol Sci, 2020 S0923-1811(20)30271-1
- J Cancer, 2020 11(18):5432-5439
- Biochem Cell Biol, 2020 25;1-6
- Mol Biomed, 2020 1(1):12
- Theranostics, 2019 9(13):3840-3852
- Clin Cancer Res, 2019 10.1158/1078-0432
- EBioMedicine, 2019 40:210-223
- Br J Cancer, 2019 10.1038/s41416-019-0608-1
- Oncogene, 2019 38(45):7046-7059
- Int J Cancer, 2019 10.1002/ijc.32609
- FASEB J, 2019 33(1):1151-1166
- Molecules, 2019 24(23)
- Mol Cell Biochem, 2019 450(1-2):87-96
- Mol Cell Endocrinol, 2019 491:110432
- Cancer Med, 2019 8(8):3892-3904
- J Cancer, 2019
- Cell Biol Int, 2019 43(10):1174-1183
- Gene, 2019 712:143956
- Cancer Manag Res, 2019 11:10107-10115
- Biochem Biophys Res Commun, 2019 515(2):275-281
- J Clin Invest, 2018 1;128(3):970-984
- Adv Sci (Weinh), 2018 5(8):1800034
- Biomaterials, 2018 181:268-279
- Theranostics, 2018 8(5):1256-1269
- EBioMedicine, 2018 35:142-154
- Cancer Lett, 2018 423:36-46
- Cell Death Dis, 2018 9(2):92
- J Crohns Colitis, 2018 12(8):993-1004
- Biochim Biophys Acta Mol Basis Dis, 2018 1864(5 Pt A):1744-1753
- Life Sci, 2018 215:73-79
- J Cell Physiol, 2018 233(6):4972-4980
- Biochim Biophys Acta Gene Regul Mech, 2018 10.1016/j.bbagrm.2018.07.004
- Onco Targets Ther, 2018 11:2581-2591
- Exp Cell Res, 2018 371(1):63-71
- World Neurosurg, 2018 117:e269-e279
- Theranostics, 2017 7(5):1114-1132
- Int J Mol Sci, 2017 18(10)
- Oncol Rep, 2017 38(4):2498-2506
- Clin Cancer Res, 2016 10.1158/1078-0432
- J Exp Clin Cancer Res, 2016 35(1):134
- J Clin Endocrinol Metab, 2016 10.1210/jc.2016-1120
- Oncotarget, 2016 7(20):28976-88
- Am J Cancer Res, 2016 6(12):2816-2830
- Onco Targets Ther, 2016 9:5371-81
- Hua Xi Kou Qiang Yi Xue Za Zhi, 2016 34(3):286-90
- J Biol Chem, 2015 290(32):19387-401
- J Exp Med, 2014 211(11):2249-63
- Laser Phys Lett, 2014 11(11)
化学信息&溶解度
分子量 | 718.79 |
分子式 | C41H42N4O8 |
CAS号 | 129497-78-5 |
Smiles | COC(=O)CCC1=C(C)C2=CC3=NC(=CC4=C(C)C(=C([NH]4)C=C5N=C(C=C1[NH]2)C(=C5C)CCC(O)=O)C=C)C6=CC=C(C(C(=O)OC)C36C)C(=O)OC |
储存条件(自收到货起) | 3年 -20°C(避光) 粉状 |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 139.12 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 139.12 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 139.12 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 139.12 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 139.12 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 |
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。